Sarkoidozda Pulmoner Rehabilitasyon

Yıl 2023, Cilt: 5 Sayı: 3, 189 - 197, 30.10.2023

Nisanur Tutuş Esra Pehlivan

https://doi.org/10.57224/jhpr.1072917

Öz

Sarkoidozlu bireylerde; egzersiz intoleransı ve kas zayıflığı gibi yaşam kalitesini etkileyen semptomların sıklıkla görülmesi nedeniyle bireylere mümkün olduğunca aktif ve katılımcı bir yaşam sürmeleri önerilmektedir. Sarkoidozun karmaşıklığı ve çoklu sistem tutulumu potansiyeli göz önüne alındığında, rehabilitasyon veya fiziksel egzersiz programları da dahil olmak hastaya yönelik terapötik yaklaşımın kapsamlı ve bireyselleştirilmiş olması gerekmektedir. Sarkoidozlu bireylerin bu heterojenliği, standart pulmoner rehabilitasyon programının modifikasyonunu gerektirebilir. Bütün bu bilgilerden yola çıkarak sarkoidozlu bireylerde optimal bir egzersiz programının (egzersiz türleri, yoğunluklar, sıklık ve süre) tanımlanması için daha geniş kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

egzersiz, pulmoner rehabilitasyon, sarkoidoz

Kaynakça

• 1. Grunewald J, Grutters JC, Arkema E V, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Prim 2019;5(1), 45.
• 2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2), 736–55.
• 3. Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of Sarcoidosis. Clin Chest Med. 2015;36(4), 727–37.
• 4. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Lancet (London, England) 2014;383(9923), 1155–67.
• 5. Marcellis RGJ, Lenssen AF, Elfferich MDP, De Vries J, Kassim S, Foerster K, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011;38(3),628–34.
• 6. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012;40(1), 255–63.
• 7. Drent M, Marcellis R, Lenssen A, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31(2), 117–28.
• 8. Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJT, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005;60(1), 32–8.
• 9. Panagiotou M, Polychronopoulos V, Strange C. Respiratory and lower limb muscle function in interstitial lung disease. Chron Respir Dis 2016;13(2), 162–72.
• 10. Strookappe B, Saketkoo LA, Elfferich M, Holland A, De Vries J, Knevel T, et al. Physical activity and training in sarcoidosis: review and experience-based recommendations. Expert Rev Respir Med 2016;10(10), 1057–68.
• 11. Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012;106(3), 429–35.
• 12. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015;25(3), 1–72.
• 13. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188(8), 13-64.
• 14. Marcellis RGJ, Lenssen AF, de Vries J, Drent M. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013;19(5), 524–30.
• 15. Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. Am J Hosp Palliat Care 2014;31(5), 562–75.
• 16. Petri MA, Martin RS, Scheinberg MA, Furie RA. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. Lupus 2017;26(1), 27–37.
• 17. Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford) 2009;48(12), 1533–6.
• 18. Marcellis R, Van der Veeke M, Mesters I, Drent M, De Bie R, De Vries G, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis 2015;32(1), 53–62.
• 19. Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of Physical Training in Sarcoidosis. Lung 2015;193(5), 701–8.
• 20. Saketkoo LA, Karpinski A, Young J, Adell R, Walker M, Hennebury T, et al. Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis. ERJ Open Res 2018;4(2), 00085-2017.
• 21. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001;120(1), 102–8.
• 22. Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012;29(2), 139–46.
• 23. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager HJ, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164(10), 1885–9.
• 24. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue Is Associated With Quality of Life in Sarcoidosis Patients. Chest 2006;130(4), 989–94.
• 25. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Int J Med 2006;99(5), 307–15.
• 26. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 2008;102(12), 1675–80.
• 27. Cremers JP, Drent M, Elfferich MD, Nelemans PJ, Wijnen PA, Witteman BJ, et al. Body composition profiling in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2013;30(4), 289–99.
• 28. Wirnsberger RM, Drent M, Hekelaar N, Breteler MH, Drent S, Wouters EF, et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997;10(7), 1450–5.
• 29. Bechman K, Christidis D, Walsh S, Birring SS, Galloway J. A review of the musculoskeletal manifestations of sarcoidosis. Rheumatology 2018;57(5), 777–83.
• 30. Myers GB, Gottlieb AM, Mattman PE, Eckley GM, Chason JL. Joint and skeletal muscle manifestations in sarcoidosis. Am J Med 1952;12(2), 161–9.
• 31. Maeshima S, Koike H, Noda S, Noda T, Noda T, Nakanishi H, Iijima M, Ito M, Kimura S, Sobue G. Clinicopathological features of sarcoidosis manifesting as generalized chronic myopathy. J Neurol 2015;262(4), 1035–45.
• 32. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35(1), 17–23.
• 33. Schreiber T, Windisch W. Respiratory muscle involvement in sarcoidosis. Expert Rev Respir Med 2018;12(7), 545–8.
• 34. Costabel U. Skeletal muscle weakness, fatigue and sarcoidosis. Thorax 2005;60(1), 1–2.
• 35. Weiner P, Azgad Y, Weiner M. The effect of corticosteroids on inspiratory muscle performance in humans. Chest 1993;104(6), 1788–91.
• 36. Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E. Respiratory diseases and muscle dysfunction. Expert Rev Respir Med 2012;6(1), 75–90.
• 37. Wallaert B, Talleu C, Wemeau-Stervinou L, Duhamel A, Robin S, Aguilaniu B. Reduction of Maximal Oxygen Uptake in Sarcoidosis: Relationship with Disease Severity. Respiration 2011;82(6), 501–8.
• 38. Barros WGP, Neder JA, Pereira CAC, Nery LE. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004;71(4), 367–73.
• 39. Miller A, Brown LK, Sloane MF, Bhuptani A, Teirstein AS. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995;107(2), 323–9.
• 40. Hoitsma E, Marziniak M, Faber CG, Reulen JPH, Sommer C, De Baets M, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002;359(9323), 2085–6.
• 41. Bakkers M, Merkies ISJ, Lauria G, Devigili G, Penza P, Lombardi R, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009;73(14), 1142–8.
• 42. Hoitsma E, Reulen JPH, de Baets M, Drent M, Spaans F, Faber CG. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004;227(1), 119–30.
• 43. Tavee J, Zhou L. Small fiber neuropathy: A burning problem. Cleve Clin J Med 2009;76(5), 297–305.
• 44. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010;80(3), 212–9.
• 45. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest 2004;125(3), 997–1004.
• 46. Pereira CAC, Dornfeld MC, Baughman R, Judson MA. Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med 2014;20(5), 496–502.
• 47. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med 2007;28(1), 121–7.
• 48. Holtzman S, Newth S, Delongis A. The role of social support in coping with daily pain among patients with rheumatoid arthritis. J Health Psychol 2004;9(5), 677–95.
• 49. Korenromp IHE, Heijnen CJ, Vogels OJM, van den Bosch JMM, Grutters JC. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011;140(2), 441–7.
• 50. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287(10), 1301–7.
• 51. Migita K, Sasaki Y, Ishizuka N, Arai T, Kiyokawa T, Suematsu E, et al. Glucocorticoid Therapy and the Risk of Infection in Patients With Newly Diagnosed Autoimmune Disease. Medicine 2013;92(5), 285–93.
• 52. Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM 3rd, Hunder GG, Gabriel SE. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheumatol 2007;57(2), 279–86.
• 53. Verbraecken J, Hoitsma E, van der Grinten CPM, Cobben NAM, Wouters EFM, Drent M. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21(2), 137–46.
• 54. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012;8(1), 95–103.
• 55. Van Manen MJG, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, et al. Validation of the King’s Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2016;33(1), 75–82.
• 56. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS. The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013;68(1), 57–65.
• 57. Guber E, Wand O, Epstein Shochet G, Romem A, Shitrit D. The Short- and Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature. Respiration 2021;100(5), 423–31.
• 58. Grongstad A, Spruit MA, Oldervoll LM, Vøllestad NK, Edvardsen A. Pulmonary Rehabilitation in Patients with Pulmonary Sarcoidosis: Impact on Exercise Capacity and Fatigue. Respiration 2020;99(4), 289–97.
• 59. Lingner H, Buhr-Schinner H, Hummel S, van der Meyden J, Grosshennig A, Nowik D, et al. Short-Term Effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for Patients with Sarcoidosis: The ProKaSaRe Study. Respiration 2018;95(5), 343–53.
• 60. Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A randomızed controlled trial. J Cardiopulm Rehabil Prev 2018;38(2), 124–30.
• 61. Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial. Respir Med Res 2020;77, 1–7.
• 62. Strookappe B, Elfferich M, Swigris J, Verschoof A, Veschakelen J, Knevel T, et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015;32(1), 43–52.
• 63. Grongstad A, Vøllestad NK, Oldervoll LM, Spruit MA, Edvardsen A. The acute impact of resistance training on fatigue in patients with pulmonary sarcoidosis. Chron Respir Dis 2020;17, 1479973120967024.
• 64. Kullberg S, Rivera N V, Eriksson MJ, Grunewald J, Eklund A. High-intensity resistance training in newly diagnosed sarcoidosis- an exploratory study of effects on lung function, muscle strength, fatigue, dyspnea, health-related quality of life and lung immune cells. Eur Clin Respir J 2020;7(1), 1730137.
• 65. Grongstad A, Vøllestad NK, Oldervoll LM, Spruit MA, Edvardsen A. The effects of High- versus Moderate-Intensity Exercise on Fatigue in Sarcoidosis. J Clin Med 2019;8(4), 460.
• 66. Karadallı MN, Boşnak-Güçlü M, Camcıoğlu B, Kokturk N, Türktaş H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care 2016;61(4), 483–94.
• 67. Boots AW, Drent M, de Boer VCJ, Bast A, Haenen GRMM. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 2011;30(4), 506–12.